Skip to main content

Table 2 Hazard ratios (HR) and 95% confidence intervals (CI) of prognostic factors in patients with invasive breast cancer by univariate and multivariate Cox regression analysis

From: Aggressive primary treatments with favourable 5-year survival for screen-interval breast cancers

  Univariate analysis Multivariate analysis
    With adjustment on TNM stage Without adjustment on TNM stage
HR 95% CI p HR 95% CI p HR 95% CI p
Mode of detection    < 0.001    0.325    < 0.001
 NSP group 1    1    1   
 SP group 0.25 0.17–0.37   0.75 0.48–1.15   0.28 0.19–0.42  
 IC group 0.51 0.29–0.87   0.74 0.42–1.30   0.48 0.28–0.83  
Age    0.128    0.003    0.05
  > 65 years 1    1    1   
  ≤ 65 years 0.77 0.54–1.08   0.58 0.41–0.84   0.70 0.49–0.99  
TNM stage    < 0.001    < 0.001   
 I 1    1     
 II 2.62 1.40–4.90   2.59 1.33–5.02   
 III 14.48 8.03–26.09   13.25 7.02–25.01   
 IV 76.92 44.12–134.08   63.69 33.69–120.39   
SBR grade    < 0.001     
 1 1       
 2 3.02 1.56–5.84    
 3 5.82 2.93–11.59    
Hormonal receptor status    < 0.001    < 0.001    < 0.001
 OR+/PR+ 1    1    1   
 OR+/PR- or OR-/PR+ 2.78 1.82–4.25   1.97 1.28–3.02   2.49 1.63–3.81  
 OR-/PR- 4.30 2.87–6.45   2.88 1.89–4.38   3.89 2.58–5.87  
Her-2 receptor status    0.050     
 Positive 1       
 Negative 0.63 0.40–1.00    
Type of treatment    < 0.001     
 Surgery ± RT 1       
 Surgery + CT ± RT 3.75 2.18–6.45    
 Neoadjuvant treatment + Surgery ± RT/CT 11.36 6.33–20.39    
 Absence of surgery 84.72 48.26–148.73    
  1. SP group, patients detected by the screening programme; IC group, patients with interval cancer; NSP group, patients detected without participating in the screening programme; SBR, Scarff-Bloom-Richardson grade; OR, oestrogen receptor; PR, progesterone receptor; RT, adjuvant radiotherapy; CT, adjuvant chemotherapy